Das maligne Pleuramesotheliom

Zusammenfassung

Das maligne Pleuramesotheliom (MPM) ist ein bösartiger und sehr aggressiver Tumor, der seinen Ursprung in den mesothelialen Oberflächen der Pleura nimmt. Die Hauptursache des MPM ist die Inhalationsexposition gegenüber Asbest. Hier kann die Latenzzeit jedoch 30–60 Jahre betragen. Die klinischen Symptome sind meist unspezifisch. Die Diagnosestellung eines MPM sollte mittels adäquater Gewebegewinnung erfolgen. Die beste Aussagekraft zeigt hier die diagnostische Videothorakoskopie (VATS). MPM werden hauptsächlich in epitheloide, sarkomatoide und biphasische (gemischte) Subgruppen unterteilt. Vor der interdisziplinären Festlegung eines multimodalen Therapieregimes ist ein dezidiertes, u. U. auch invasives Staging erforderlich. Eine multimodale Therapie ist – falls sich der Patient hierfür funktionell und onkologisch qualifiziert – allen anderen Monotherapien überlegen. Das Ziel der chirurgischen Therapie ist die makroskopisch komplette Resektion des Tumors. Grundsätzlich stehen in der operativen Behandlung des MPM 2 verschiedene, konkurrierende Resektionsphilosophien zur Verfügung: die extrapleurale Pneumonektomie (EPP) und die radikale Pleurektomie (RP). Ein Paradigmenwechsel hat in den letzten Jahren stattgefunden: RP ist die inzwischen präferierte Resektionsbehandlung geworden.

Abstract

Malignant pleural mesotheliomas (MPM) are very aggressive tumors, which originate from the mesothelial cells of the pleural surface. The main risk factor associated with MPM is exposure to asbestos. The latency period between asbestos exposure and MPM can be 30–60 years. Clinical symptoms and signs are often nonspecifc. The diagnosis of MPM requires an adequate tissue specimen for pathological examination, and video assisted thoracoscopic surgey (VATS) is associated with the highest diagnostic yield. MPM are histologically classified into epitheloid, sacromatoid and biphasic (mixed) sub-types. Accurate staging with invasive tests, if needed, is an important step before an interdisciplinary team can decide on an optimal (multi-modal) treatment approach. A multi-modal treatment approach (surgery, radiation oncology and chemotherapy) is superior to all approaches relying only on a single modality, if the patient qualifies for it from an oncological and functional standpoint. The goal of the surgical therapy is to achieve macroscopic complete resection. There are two competing surgical approaches and philosophies: extrapleural pneumonectomy (EPP) and radical pleurectomy (RP). Over the last years a paradigm shift from EPP to RP occurred and RP is now often the preferred surgical option.

Key words

Pleuramesotheliom - multimodale Therapie - radikale Pleurektomie

Key words

malignant pleural mesothelioma - multimodal treatment - radical pleurectomy

• Literatur

• 1 Neumann V, Löseke S, Nowak D et al. Malignant pleural mesothelioma – incidence, etiology, diagnosis, treatment and occupational health. Dtsch Arztebl Int 2013; 110: 319-326
• 2 Kaatsch P, Spix C, Hentschel S et al. Beiträge zur Gesundheitsberichterstattung des Bundes. Krebs in Deutschland 2009/2010. 9. Aufl. Berlin: Robert Koch-Institut; 2013
• 3 Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603
• 4 Schönfeld I, Kraywinkel K. Epidemiological cancer data online: an overview of information service in Germany and Europe. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2014; 57: 22-26
• 5 Hollevoet K, Reitsma JB, Creaney J et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 1541
• 6 Pass HI, Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564
• 7 Pass HI, Levin SM, Harbut MR et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417
• 8 Bueno R, Reblando J, Glickman J et al. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004; 78: 1774-1776
• 9 Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleura mesothelioma. Eur Respir J 2010; 35: 479-495
• 10 Travis WD, Colby TV, Corrin B, Shimasato Y, Brambila E. Histological classification of lung and pleural tumors. WHO-blue Book. 3rd. ed. Berlin, Heidelberg, New York: Springer; 1999
• 11 Larson T, Melnikova N, Davis SI et al. Incidence and descriptive epidemiology of mesothelioma in the United States, 1999–2002. Int J Occup Environ Health 2007; 13: 398-403
• 12 Bölükbas S, Manegold C, Eberlein M et al. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer 2011; 71: 75-81
• 13 Bölükbas S, Eberlein M, Fisseler-Eckhoff A et al. Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections. Lung Cancer 2013; 81: 241-246
• 14 Bölükbas S, Eberlein M, Kudelin N et al. Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG-stage III malignant pleural mesothelioma. Eur J Cardiothorac Surg 2013; 44: 119-123
• 15 Friedberg JS, Culligan MJ, Mick R et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 2012; 93: 1658-1667
• 16 Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-1202
• 17 de Perrot M, Feld R, Cho BC et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant highdose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413-1418
• 18 Chailleux E, Dabouis G, Pioche D et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988; 93: 159
• 19 Ramalingam SS, Belani CP. Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol 2008; 3: 1056-1064
• 20 Mossman BT, Shukla A, Heintz NH et al. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 2013; 182: 1065-1077
• 21 van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889
• 22 Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644
• 23 Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38: 111-121
• 24 Ceresoli GL, Zucali PA, De Vincenzo F et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011; 72: 73-77
• 25 Zucali PA, Simonelli M, Michetti G et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012; 75: 360-377
• 26 Xanthopoulos A, Bauer TT, Blum TG et al. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 2008; 3: 34
• 27 Zucali PA, Ceresoli GL, Garassino I et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008; 112: 1555-1561
• 28 Marcq E, Pauwels P, van Meerbeeck JP et al. Targeting immune checkpoints: New opportunity for mesothelioma treatment?. Cancer Treat Rev 2015; 41: 914-924
• 29 Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754-758
• 30 Lee C, Bayman N, Swindell R et al. Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice. Lung Cancer 2009; 66: 150-156
• 31 Gupta V, Mychalczak B, Krug L et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005; 63: 1045-1052
• 32 Rusch VW, Rosenzweig K, Venkatraman E et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122: 788-795
• 33 Ramalingam SS, Belani CP. Recent advances in the treatment of malignant pleural mesothelioma. J Thorac Oncol 2008; 3: 1056-1064
• 34 Tselis N, Ferentinos K, Kolotas C et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol 2011; 6: 545-552
• 35 Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol 2006; 1: 175-176
• 36 Bölükbas S, Eberlein M, Schirren J. Thoracic shaping technique to avoid residual space after extended pleurectomy/decortication. Eur J Cardiothorac Surg 2013; 44: 563-564
• 37 Lang-Lazdunski L, Bille A, Papa S et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience. J Thorac Cardiovasc Surg 2015; 149: 558-566
• 38 Sugarbaker DJ, Gill RR, Yeap BY et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 2013; 145: 955-963
• 39 Hatz RA, Klotz LV. Pleuramesotheliome. Onkologe 2015; 21: 1129-1136
• 40 Utley M, Fiorentino F, Treasure T. Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma. Eur J Cardiothorac Surg 2010; 38: 241-244
• 41 Treasure T, Internullo E, Florentino F. A survey of opinions and beliefs concerning surgery for malignant pleura. mesothlioma amongst 802 members of the European Association for Cordio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS). Interact Cardiovasc Thorac Surg 2011; 12: 341-346
• 42 Cao C, Tian D, Park J et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 2014; 83: 240-245
• 43 Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135: 620-626
• 44 Krug LM, Pass HI, Rusch VW et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007-3013
• 45 Bölükbas S, Eberlein M, Schirren J. Recurrence of malignant pleural mesothelioma at the resection borders – local or distant recurrence?. J Thorac Oncol 2013; 8: e65
• 46 Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999; 68: 1799-1804
• 47 Ploenes T, Osei-Agyemang T, Krohn A et al. Changes in lung function after surgery for mesothelioma. Asian Cardiovasc Thorac Ann 2013; 21: 48-55
• 48 Bölükbas S, Eberlein M, Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 900-905
• 49 Mollberg NM, Vigneswaran Y, Kindler HL et al. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg 2012; 94: 1086-1092
• 50 Sharkey AJ, Tenconi S, Nakas A et al. The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg 2016; 49: 1632-1641
• 51 Batirel HF, Metintas M, Caglar HB et al. Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy. J Thorac Cardiovasc Surg 2016; 151: 478-484